Tovey Christopher J. 4
4 · Jazz Pharmaceuticals plc · Filed Jul 7, 2022
Insider Transaction Report
Form 4
Tovey Christopher J.
EVP COO & Managing Dir EUR/INT
Transactions
- Exercise/Conversion
Ordinary Shares
2022-07-05$0.02/sh+4,032$81→ 19,872 total - Sale
Ordinary Shares
2022-07-05$160.00/sh−4,032$645,120→ 15,840 total - Sale
Ordinary Shares
2022-07-05$160.00/sh−1,177$188,320→ 14,663 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-07-05−4,032→ 4,031 totalExercise: $0.02Exp: 2031-02-22→ Ordinary Shares (4,032 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.